Ozempic and Wegovy Vision Loss (NAION) Lawsuits

Updated October 2026

Lawsuits allege that GLP-1 drugs such as Ozempic and Wegovy can cause non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of blood flow to the optic nerve that can cause permanent vision loss, usually in one eye.

In June 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide, the active ingredient in Ozempic and Wegovy. U.S. labels do not include a NAION warning.

Where the Litigation Stands

• Case: In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, U.S. District Court for the Eastern District of Pennsylvania, before Judge Karen S. Marston.
• Formed: December 2025, separate from the GLP-1 digestive-injury litigation.
• Size: 247 cases were pending as of October 1, 2026.
• Next steps: discovery and briefing on whether the drugs can cause NAION continue into 2027. No trial dates are set.

Drugs Involved

• Novo Nordisk: Ozempic, Wegovy, Rybelsus, Saxenda
• Eli Lilly: Trulicity, Mounjaro, Zepbound

Who May Qualify

• You took one of these drugs
• You were diagnosed with NAION or ischemic optic neuropathy by an eye doctor
• You have lasting vision loss in one or both eyes

What to Gather

• Pharmacy records for the GLP-1 drug
• Ophthalmology records showing the NAION diagnosis
• The approximate date your vision changed

Frequently Asked Questions

I lost vision but no one called it NAION. Can I still ask?

Yes. We can review your eye records with you to see what diagnosis was made.

I took a compounded semaglutide. Does that count?

Possibly, but claims against compounding pharmacies are different from claims against the brand manufacturers. Tell us what you took.

Is there a deadline?

Yes. California deadlines usually run from when you learned of the injury and its possible cause. Ask early.